Expiring federal contract · order under a contract vehicle
36C25524F0066 — Ino Therapeutics LLC
Department of Veterans Affairs
- Contract / PIID
- 36C25524F0066
- Incumbent
- Ino Therapeutics LLC
- Incumbent UEI
- XXQHL619FUN6
- Current end date
- July 6, 2027
- Potential total value
- $213,879
- Obligated
- $213,879
- NAICS
- 325412 — Pharmaceutical Preparation Manufacturing
- PSC
- 6505 — DRUGS AND BIOLOGICALS
- Set-aside
- Not stated
- Start date
- July 7, 2024
- Place of performance
- MO
- Award type
- DELIVERY ORDER
Source: USASpending.gov award record, last checked September 19, 2026. Place of performance as reported by USASpending.
What the contract covers
INOMAX INHALED NITRIC OXIDE WITH DELIVERY SYSTEM
Likely rebid window (estimate)
- Sources Sought / RFI: about Jul 2026 – Jan 2027 (6–12 months before the end date)
- RFP: about Mar 2027 – May 2027 (2–4 months before the end date)
Now inside the estimated Sources Sought / RFI window.
This is an order under contract vehicle V797D60737. Orders are usually not competed on their own: the next order may be placed under the same vehicle.
Estimated from the current end date using typical federal recompete timing. Agencies set their own schedules, and contracts are often extended. This is not a published solicitation date.
Track this recompete free
- Change history: no changes recorded since Mindy began tracking this contract.
- Alerts: get an email when the end date moves or the follow-on is posted.
- Contacts: the buying office and small-business contacts for this agency.
Other contracts expiring at Department of Veterans Affairs (NAICS 325412)
- 36C25927F0028 — Janssen Biotech INC · ends November 20, 2026 · $385K
- 36C24126F0039 — Medi-physics, INC. · ends November 21, 2026 · $100K
- 36C25026N0181 — Schaaf Drugs, LLC · ends November 22, 2026 · $681K
- 36C24626N0323 — Cardinal Health 414, LLC · ends November 30, 2026 · $323K
- 36C25226P0101 — Petnet Solutions, INC. · ends November 30, 2026 · $110K
- 36C26023P0532 — Cardinal Health 414, LLC · ends November 30, 2026 · $337K
- 36C26224P0297 — Rls (USA) INC. · ends November 30, 2026 · $1.1M
- 36C26226N0112 — Novartis Pharmaceuticals Corporation · ends November 30, 2026 · $4.3M
- 36C26227N0156 — Novartis Pharmaceuticals Corporation · ends November 30, 2026 · $769K
- 36C24726F0053 — Exelan Pharmaceuticals INC · ends December 7, 2026 · $4.8M